PDF
Print

Trasylol

Trasylol Litigation at The Lanier Law Firm

Trasylol (aprotinin injection) was approved by the Food & Drug Administration in 1993 and was used to stop bleeding during heart bypass surgery.

A January 2006 New England Journal of Medicine article linked the use of Trasylol to kidney damage, heart attacks and strokes. In addition, the same researchers completed a February 2007 study published in the Journal of the American Medical Association, which found patients on Trasylol were at greater risk of dying over the next five years than those given two other medications.

Not until November 2007 did Bayer Pharmaceuticals Corp. agree to a marketing suspension of Trasylol. The marketing suspension came two weeks after a major Canadian drug trial was terminated because of an increase in deaths for cardiac surgery patients using Trasylol.

In a February 2008 interview for CBS News’ “60 Minutes,” Dr. Dennis Mangano said the FDA should have pulled Trasylol following his NEJM study. "Between my study and November 5, when it was taken off the market, there were approximately 431,000 patients who received the drug. As I calculated, 22,000 lives could have been saved. It's about a 1,000 lives saved per month delay in taking that drug off the market," he said in the interview.

If you or a loved one has received Trasylol and suffered any side effects, please contact our office for a free evaluation.

Trasylol Litigation Links:

CBS ’60 Minutes’ report on Trasylol

FDA Requests Marketing Suspension of Trasylol

FDA Public Health Advisory for Trasylol

New England Journal of Medicine article on Trasylol